Exclusive license ag
Exclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract.
05 mars 2024 03h10 HE | Everzom
Exclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract. This new worldwide license...
Licence exclusive av
Licence exclusive avec Erganeo pour EVerGel, premier candidat médicament d’EVerZom, un traitement révolutionnaire des fistules et de la fibrose du tube digestif.
05 mars 2024 03h10 HE | Everzom
Licence exclusive avec Erganeo pour EVerGel, premier candidat médicament d’EVerZom, un traitement révolutionnaire des fistules et de la fibrose du tube digestif. Cette nouvelle licence mondiale est...
Logo.png
Crohn's Disease Treatment Drug Market is Expected to Showcase a Significant Growth During Study Period (2019–2032) | DelveInsight
06 févr. 2024 13h00 HE | DelveInsight Business Research LLP
New York, USA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Crohn's Disease Treatment Drug Market is Expected to Showcase a Significant Growth During Study Period (2019–2032) | DelveInsight  The Crohn's...
ABIVAX_Logo-RGB.png
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
02 févr. 2024 02h30 HE | Abivax
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease Obefazimod Crohn’s Disease (CD) IND filed with the FDA in December...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
25 janv. 2024 08h05 HE | Organovo, Inc.
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD),...
Organovo Logo (2 Color Med-Res-082117).png
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
09 janv. 2024 08h05 HE | Organovo, Inc.
SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD),...
When it Comes to Tre
When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…
30 nov. 2023 10h59 HE | Spherix Global Insights
Exton, Pennsylvania, Nov. 30, 2023 (GLOBE NEWSWIRE) -- With the Ulcerative Colitis (UC) market set to heat up in the coming months, the JAK class seems poised to become a dominant treatment,...
Biora-tm_rgb.jpg
Biora Therapeutics Submits Updated IND Application for BT-600
30 oct. 2023 16h05 HE | Biora Therapeutics, Inc.
Update includes supplemental information and provides additional time to complete regulatory review; company expects to remain on track with Ph1 timeline.
Capture_brand and logo.PNG
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
03 août 2023 07h05 HE | Morphic Therapeutic
-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Greater...
TIP_link_300x300.jpg
4.9% CAGR for Gastrointestinal Drugs Market Size Worth $71.3Bn, Globally, by 2027 with Irritable Bowel Syndrome Segment Driving Growth During 2020-2027 | Report by The Insight Partners
11 juil. 2023 10h55 HE | The Insight Partners
Pune, India, July 11, 2023 (GLOBE NEWSWIRE) -- The Insight Partners latest study on "Gastrointestinal Drugs Market Size Report, Forecast to 2027 – COVID-19 Impact and Global Analysis – by Drug...